---
title: "Cormedix 完成了对 Melinta Therapeutics 的收购，提高了财务指引，并宣布了新的领导团队"
description: "- CorMedix 的一项变革性交易，扩展和多样化了公司的商业产品组合，包含七种创新药物产品以及一个具有近期收入增长潜力的管线扩展指示 -"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255617485.md"
published_at: "2025-09-02T12:09:09.000Z"
---

# Cormedix 完成了对 Melinta Therapeutics 的收购，提高了财务指引，并宣布了新的领导团队

> - CorMedix 的一项变革性交易，扩展和多样化了公司的商业产品组合，包含七种创新药物产品以及一个具有近期收入增长潜力的管线扩展指示 -

\- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

### Related Stocks

- [CRMD.US - CorMedix](https://longbridge.com/zh-CN/quote/CRMD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead | CorMedix (NASDAQ:CRMD) announced a strategic shift from a single-product renal company to a diversified specialty pharma | [Link](https://longbridge.com/zh-CN/news/275523726.md) |
| CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback | CorMedix Inc. (NASDAQ:CRMD) has announced a share repurchase program approved by its board, allowing for up to $75 milli | [Link](https://longbridge.com/zh-CN/news/275654068.md) |
| Analyst Expectations For Cormedix's Future | In the past three months, six analysts have rated Cormedix (NASDAQ:CRMD), showing a mix of bullish to bearish sentiments | [Link](https://longbridge.com/zh-CN/news/275609296.md) |
| CorMedix Announces $75 Mln Share Buyback Program | CorMedix Therapeutics (CRMD) has announced a share repurchase program of up to $75 million, approved by its Board, to be | [Link](https://longbridge.com/zh-CN/news/274523823.md) |
| CorMedix Hosts Analyst Day to Showcase Pipeline and Growth Drivers | CorMedix Inc. will host an analyst day on February 10, 2026, in New York, featuring presentations from key opinion leade | [Link](https://longbridge.com/zh-CN/news/274158609.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。